Azilsartan Kamedoxomil; Chlorthalidone Patent Expiration

Azilsartan Kamedoxomil; Chlorthalidone is Used for managing high blood pressure. It was first introduced by Azurity Pharmaceuticals Inc in its drug Edarbyclor on Dec 20, 2011.


Azilsartan Kamedoxomil; Chlorthalidone Patents

Given below is the list of patents protecting Azilsartan Kamedoxomil; Chlorthalidone, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Edarbyclor US9387249 Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone Jul 01, 2031 Azurity
Edarbyclor US9169238 Solid pharmaceutical composition Feb 04, 2030 Azurity
Edarbyclor US9066936 Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent Mar 26, 2028 Azurity
Edarbyclor US7157584 Benzimidazole derivative and use thereof May 22, 2025 Azurity
Edarbyclor US7572920 Benzimidazole derivative and use as a II receptor antagonist Jan 07, 2025 Azurity
Edarbyclor US5583141 Heterocyclic compounds and their use as angiotensin antagonists Dec 10, 2013

(Expired)

Azurity



Azilsartan Kamedoxomil; Chlorthalidone's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List